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The Fifth World Symposium on Pulmonary Hypertension
Nazzareno Galiè, MD,* Gerald Simonneau, MDy
Bologna, Italy; and Paris, FranceSometimes pivotal events can be identiﬁed in the history of
a disease that mark the borders of different eras in the
diagnosis or treatment. One of these pivotal events in the
history of pulmonary arterial hypertension (PAH) was the
publication in 1996 of the paper of Barst et al. (1) on
continuous intravenous epoprostenol therapy for primary
pulmonary hypertension. For the ﬁrst time, a medical therapy
was shown to reduce substantially the mortality of a disease
deﬁned as the “kingdom of the near dead” (2). In her out-
standing career, Dr. Barst made considerable contributions to
the additional pivotal events in the PAH history, which can
be identiﬁed in the World Symposia on Pulmonary Hyper-
tension (WSPH) that has been held since 1973. The inﬂu-
ence of Dr. Barst spanned every aspect of the disease from
pediatrics to adulthood and from genetics to randomized,
controlled trials (RCTs). Her interventions in the discussions
were unmistakable and full of energy and passion, and this
passion also characterized her last days when the energy was
fading.We miss her, and we would like to remember her with
the last gift she has left us: the example of a physician and
a scientist fully engaged in her activity until the end of her life.
Even if she was not able to personally attend the meeting, we
dedicate the 5th WSPH to her memory.
The achievements of the differentWSPH have marked the
progress made on this condition. The ﬁrstWSPHwas held in
Geneva, Switzerland, in 1973 and was organized by the
World Health Organization because of an epidemic of PAH
cases due to the use of aminorex, an anorexigen drug (3). A
simple clinical classiﬁcation was proposed at this meeting
(primary, secondary, and associated pulmonary hypertension
[PH]) together with the hemodynamic deﬁnition of the
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primary pulmonary hypertension was launched after this ﬁrst
symposium (4).
The second WSPH was held 25 years later in 1998 in
Evian, France. There were multiple reasons for starting the
modern series of WSPH, including the availability of 2 very
effective treatments such as epoprostenol (1) and high doses
of calcium channel blockers in patients responding to acute
vasoreactivity tests (5). A more comprehensive clinical
classiﬁcation, including 5 groups, was proposed for the ﬁrst
time at the symposium, and this facilitated both clinical
practice and the clinical research.
In fact, in the third WSPH, which was held in Venice,
Italy, in 2003, there were already 3 classes of drugs effective
in the treatment of PAH (prostanoids, endothelin receptor
antagonists, and phosphodiesterase type 5 inhibitors), and
a speciﬁc treatment algorithm was proposed (6). The clinical
classiﬁcation was reﬁned, including the familial form char-
acterized by the BMPR2 gene mutations (7).
The fourth WSPH was held in Dana Point, California, in
2008. New management strategies were introduced such as
the treatment of mildly symptomatic patients and the
combination and goal-oriented treatment strategies (8). The
RCT design was also discussed, including the need to use
time to clinical worsening as primary endpoint in phase III
registration studies (9).
The ﬁfthWSPHwas held in Nice, France, from February 27
to March 1, 2013; the ﬁndings and recommendations of 129
worldwide experts divided into 12 task forces operating for
12 months were discussed in front of an audience ofw1,000
physicians and representatives of the industry, patient asso-
ciations, and regulatory agencies.
The main conclusions of the task forces and the meeting
discussions are reported in the 13 articles published in
this supplement of the Journal of the American College of
Cardiology.
The Pathology and Pathobiology Task Force reports the
increasingly recognized importance of venous disease in
PH as well as the disordered metabolism and mitochondrial
structure, inﬂammation, and dysregulation of growth factors
leading to a proliferative, apoptosis-resistant state of the
pulmonary vascular cells (10).
The Genetics and Genomics Task Force conﬁrms a 75%
mutation detection rate for the known genes (BMPR2, ALK1,
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D2Endoglin, SMAD-9, CAV1) in familial PAH patients (11).
New-generation sequencing techniques have allowed the
identiﬁcation of a new recently reported gene encoding the
potassium channel KCNK3 (12). The importance of genetic
testing and counseling and genomic studies is also discussed.
The clinical and prognostic importance of the right
ventricle adaptation to the increased afterload in PH patients
is outlined by the Task Force on Pathophysiology: “adaptive”
and a “maladaptive” right ventricle phenotypes are described
with speciﬁc molecular, structural, and hemodynamic char-
acteristics (13).
An updated clinical classiﬁcation, for the ﬁrst time the
same for adult and pediatric patients, is proposed by the
speciﬁc Task Force (14). Changes includes the individual
categorization of the persistent PH of neonates; the addition
of congenital diseases in groups 2, 3, and 5; and the shifting
of PH associated with chronic hemolytic anemias from
group 1 to group 5. New drugs potentially inducing PH are
also listed.
The Task Force for Deﬁnitions and Diagnosis provides
a new hemodynamic deﬁnition of PAH, including pulmo-
nary vascular resistance, and a more accurate and standard-
ized zero level for the transducer at right heart catheterization
(15). The term “borderline PH” is discouraged and the
deﬁnition of PH on exercise is still considered not possible.
Indications for screening strategies in asymptomatic patients
and an updated diagnostic algorithm are also provided.
The Task Force on Epidemiology and Registries
describes the basic methodology by which PAH registries
have been conducted and review key insights provided by
registries (16). An analysis on the utility of data to predict
the survival outcomes is also discussed.
An updated treatment algorithm is provided by the Task
Force on Standard of Care including new published data
concerning rehabilitation, combination therapy, new
compounds (17–19), and lung transplantation (20,21). The
importance of the effect of the drugs on patient outcome is
also outlined (22).
The Task Force on Treatment Goals for PH conﬁrms the
need to analyze multiple goals for deﬁning the success of
therapy including symptoms, exercise capacity and the right
ventricular function (23). Speciﬁc absolute values for the
relevant parameters are also provided.
The Task Force on New Trial Designs and Potential
Therapies for PAH conﬁrms the need to adopt a morbidity
and mortality primary endpoint in future phase 3 random-
ized, controlled trials (24). No surrogate endpoints are
identiﬁed in PAH and correlates may be included in phase 2
studies. Different novel drugs in very early stages of devel-
opment are also reported.
The Task Force on Chronic Thromboembolic Pulmonary
Hypertension provides new diagnostic and treatment algo-
rithms for this condition (25). Pulmonary endoarterectomy is
conﬁrmed as the treatment of choice for the affected patients,
and medical therapy is used in nonoperable ones and in those
with persistent PH after surgery (26).The Task Force on PH due left heart disease and due to
lung diseases recommends that the term “out of proportion”
PH should be abandoned in both conditions (27,28). A new
nomenclature for PH due to left heart disease and the use of
the diastolic gradient (diastolic pulmonary pressure  mean
pulmonary artery wedge pressure) for the identiﬁcation of
patients with a pre-capillary PH component is reported (27).
Similarly, new deﬁnitions are provided for PH due to lung
diseases (28). Targeted therapies have not provided
convincing beneﬁts in both conditions (27,28).
The Task Force on Pediatric PH proposes new diagnostic
and treatment algorithms adapted for this group of patients
(29). The general structure is similar to the algorithms used
in the adults but takes into consideration the speciﬁc char-
acteristics and requirements of the pediatric patient
population.
In conclusion, this supplement of the Journal of the
American College of Cardiology provides the cutting-edge
knowledge in the different ﬁelds of PH, as discussed in
the ﬁfth WSPH.
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